Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly advocated for selected patients with CPM; however, opinions are divided because of the ...

The CYTO-CHIP (Cytoreductive surgery vs Cytoreductive surgery and Hyperthermic Intraperitoneal Therapy) study was an observational analysis of clinical and surgical practices concerning GC with ...

Most patients had clear cell histology and were treated with cytoreductive nephrectomy before systemic therapy. The research team found no statistical difference, regardless of patients ...

Cytoreductive surgery removes tumors that have spread throughout your abdominal cavity. It’s often combined with another procedure called hyperthermic intraperitoneal chemotherapy. You may need ...

The median follow-up was 53 months. The morbidity and mortality rates were 22.9% and 4%, respectively. The overall median survival was 19.2 months. Patients in whom cytoreductive surgery was complete ...

Early use of interferon therapy reduces the risk of secondary myelofibrosis (sMF) in young patients with essential ...

The role of secondary cytoreductive surgery is unclear. We randomly assigned patients with recurrent ovarian cancer who had a first relapse after a platinum-free interval (an interval during which ...

Standard treatment for advanced ovarian cancer – meaning it has spread beyond where the tumor first started – is cytoreductive surgery (CRS), a complicated procedure. Your ovaries and other ...

Panelists discuss how the future of polycythemia vera (PV) management will be shaped by advancements in targeted therapies, ...

Please provide your email address to receive an email when new articles are posted on . Cytoreductive surgery before chemotherapy led to significant and clinically meaningful OS and PFS benefits ...

Whether performing cytoreductive surgery before systemic therapy improves outcomes is unclear. New research findings are summarized in a short video.